I jus dun think there is much room for a drug in breast cancer. We both know arrys herb2 drug is very effective with little sides but they are shelving it. I don't own CLDX but I do intend to bet on the phase 2b data. It might be a bit premature to buy in now since the market might continue to trend down.
Market Data 
Markets 
AI
